Genotypic and Phenotypic Predictors of the Magnitude of Response to Tenofovir Disoproxil Fumarate Treatment in Antiretroviral‐Experienced Patients

Authors:

Abstract
Results from 2 placebo-controlled intensification trials of tenofovir disoproxil fumarate (DF) in treatmentexperienced human immunodeficiency type 1